Please login to the form below

Not currently logged in
Email:
Password:

Boehringer Ingelheim's Dr Susan Anton joins Icon

The CRO also appoints Dr Pui Leung, boosting its early phase and epidemiology and risk management teams

Icon has appointed former Boehringer Ingelheim director Dr Susan Anton to head up its epidemiology and risk management practice.

The move is one of two senior appointments at the contract research organisation (CRO), which also see Dr Pui Leung join at a senior clinical research physician.

Dr Anton has more than 25 years of experience leading international epidemiologic, health economic, and outcomes research, and other market access initiatives.

Most recently she served as director of US medical outcomes research and registries at Boehringer Ingelheim, and prior to that directed health economic, epidemiologic and outcomes research efforts across therapeutic areas at Bristol-Myers Squibb.

Meanwhile, Dr Leung, who will be based at Icon's clinical pharmacology unit in Manchester, UK, has 10 years of experience as a senior phase I clinical research physician in two UK CROs.

Before joining the pharmaceutical industry in 2002, he spent 13 years as a hospital physician in the UK's National Health Service (NHS).

22nd May 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics